Agilon Health, Inc. (AGL) Stock

Understand Agilon Health, Inc.: how it makes money

Agilon Health provides physician-led primary and specialty care for Medicare Advantage and Medicare FFS seniors, earning capitated per-member payments and quality-incentive savings from Medicare plans. Membership count sets the revenue base, but the thin spread between capitated rates and actual medical costs is where the stock lives or dies.

Agilon collects a fixed monthly capitation per Medicare member; every dollar of managed-care savings or quality bonus drops almost entirely to the bottom line, while every dollar of cost overage does the same in reverse.

Business quality (Weak): At a 1% operating margin and negative equity, Agilon is a barely-profitable business where a modest cost shock or a rate cut could flip it into a loss. Quality grade: Weak.

Bull case

• Quality strategy prints real savings: ACO Reach generated $229 million in gross savings at a 96% average quality score, proof that the care-coordination model converts directly into revenue rather than serving as a marketing claim.
• Clinical pathways cut hospital stays: The CHF pathway reduced inpatient first-diagnosis rates from approximately 25% to less than 5%, shifting spending from high-cost inpatient episodes to lower-cost outpatient management and protecting the capitated spread.
• Care contracts seed full-risk growth: Existing care-coordination agreements position Agilon to convert into full-risk Medicare contracts, which would lift per-member economics materially versus current shared-savings structures and deepen the moat with payers.

Bear case

• Membership is shrinking: Medicare Advantage membership fell from 498,000 to 437,000 year over year, a direct hit to the capitated revenue base that signals payer or member dissatisfaction and forces the model to rely on per-member rate increases to grow the top line.
• Cost trends still outrun rates: Medical cost trends remain elevated even after recent moderation, and with operating margin at 1%, any re-acceleration in per-member spending would push the company back into the red.
• 2027 rates are a wildcard: With 2027 Medicare Advantage payer bids still unpublished, the company cannot model its revenue for the next cycle, leaving a material uncertainty over whether capitated rates will keep pace with cost inflation.

Related Companies (Healthcare Services; 8 comparable companies)

• DaVita Inc. (DVA)
• Progyny, Inc. (PGNY)
• Sotera Health Company (SHC)
• Encompass Health Corporation (EHC)
• Option Care Health, Inc. (OPCH)
• Ardent Health Partners, LLC (ARDT)
• Select Medical Holdings Corporation (SEM)
• PACS Group, Inc. (PACS)